Acasti - ACST Total Debt to Capital

The market capitalization trend for Acasti Pharma (ACST) demonstrates the 0.00 indicator. The business's biotech sector relies on proprietary drug delivery methods for the therapy of rare heart and brain pathologies, which minimizes patent threats. Acasti Pharma (ACST) monetizes advanced CNS drug delivery methods, maintaining high profitability. Currently, Acasti Pharma (ACST) is developing a pipeline of drugs for orphan diseases, completing final tests of its core developments.

This ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the company's dependence on external creditors. By analyzing the debt-to-equity ratio, an investor can assess the resilience of Acasti Pharma (ACST) to the costs of late-stage clinical trials, where a sufficient liquidity buffer minimizes the risks of an excessive debt load.